3SOF

Hey, thanks for the link. I am aware of mostly "for pay" insider activity sites. I'll have to take a good look at this one over the weekend. Also, I am aware of Mr Swartz's buying, but I usually look for non-option or non stock plan type accumulation and it appears that his has been of the stock plan variety. I would welcome your opinion on this as I'm not too "corporate finance or accounting" knowledgeable.
Thanks again,
Jonathan

Hi jfra
I'm still learning a lot about trading and would not like to give advise and cause someone to loose money because of my opinoin's. When I buy stock based on insider buying I like to see at least three or more differant insiders buying that holds top positions in the company as an example, CEO, Chief Fianancial Officer, Director and so on along with lot's of shares being bought, the more the better. When I see insider buying that fits this example I'll look for some very positive news that will cause price movement of the stock to go up and check their prior earnings report to see if it's good or bad.
Don't know if this might help but it's a good thing to learn. I've read many times that Peter Lynch, a well known investor would say, " Why else would an insider buy unless he knew that the price of a stock is going to go up." Also when an insider buys, It can take anywhere from two weeks to six months for the stock to move so it can depend a lot on how long you're willing to hold if you buy because of insider buying.
Hope you the best of luck with you're venture in stock trading.
Another link to check for insider buying
http://insider-monitor.com/buy_today.html 

Nice run sooooo far............

Alot brewing here, could run some more but I jumped out at the close............

PPHM is a core holding of mine from 1.26; the stock was truly on fire when jfra posted his views. However, pphm got to 1.75 and then took a HUGE tumble today to 1.45. I think the stock will resume the climb as the fundamentals point to Tarcavin data being released on Feb 27th - if the dataa is positive this stock will soar

I've been posting to a different PPHM thread but I'll start posting here instead. This from the other thread:

Quote from: Lucas Scott on January 31, 2006, 11:51:49 PM
HG - thanks for updating. I played PPHM last Jan-Mar from ~1.25 to ~1.50. Today's volume was the highest in 2 years. The last time PPHM had volume better than this was during the time it ran from .70 to 2.00 in May-Jun 2003.

"T4" at Ragingbull has been a big touter of PPHM for a long time. I'm surprised the ol' windbag hasn't been around lately to pontificate about the current move. Here's the last T4 rant on PPHM. This post and some of his others are a quick way to get some DD on PPHM and Tarvacin: http://tinyurl.com/b8rve

I'm in from 1.30 last week. I almost soiled myself on the steep pullback today, but it rebounded nicely. Very nice hammer!

A ot of people sold their shares....

from 1.78....to 1.4$....could it run up


We'll see 

What's up with PPHM? No news, just sliding, sliding, sliding, like down an icy slope. The chart often precedes the news, so maybe we'll find out soon what's behind this drop.

There is a gap to fill between 1.20 and 1.25 that should get filled tomorrow. Hopefully we get some buyers at the gap fill point.

hi what do think about pphm

Good play? Nice volume today, Strong close, breaking out from symmetrical triangle pattern

Today Peregrine is on fire !
+20% in premarket...

Here's the news :

Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing
Wednesday May 24, 7:00 am ET 
- Initial Data Presented at ASM Meeting Show Complete Inhibition of Viral Replication in H5N1 In Vivo Model -
- Supported by In Vitro Data Confirming Bavituximab Binds to H5N1 Viral Particles -

Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing

Wednesday May 24, 7:00 am ET

- Initial Data Presented at ASM Meeting Show Complete Inhibition of Viral Replication in H5N1 In Vivo Model -

- Supported by In Vitro Data Confirming Bavituximab Binds to H5N1 Viral Particles -


TUSTIN, Calif. and ORLANDO, Fla., May 24 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.

"This first set of results showing that bavituximab appears to have inhibited H5N1 viral replication in the fertilized egg model and the supportive data confirming that bavituximab binds to H5N1 viral particles are encouraging," said Dr. Thorpe. "These early data support the view that bavituximab may be active against H5N1 and other common strains of influenza."

The H5N1 studies reported by Dr. Thorpe were conducted at a number of independent research laboratories. Peregrine has also been collaborating with other researchers to evaluate the potential of bavituximab delivered by different routes of administration to treat infections caused by influenza A, the viral family that includes the H5N1 strain. Peregrine has ongoing studies to evaluate various delivery methods and treatment regimens to treat influenza in a number of in vivo models, including well-established mouse and ferret models. These studies include assessments of bavituximab delivered by nasal inhalation, a form of delivery expected to be more effective than systemic delivery alone for respiratory viruses that lodge deep in the lungs.

"These early experimental data suggesting that bavituximab may have activity against the avian flu, along with preliminary data recently generated showing signs of activity in a ferret model of influenza A infection, give us momentum and direction as we pursue a variety of preclinical initiatives to assess the anti-viral potential of bavituximab," said Steven W. King, president and CEO of Peregrine. "With a repeat dose safety study in HCV patients expected to begin next month, we should be well-positioned to initiate clinical trials for bavituximab in additional indications once we have sufficient preclinical data in hand."

Bavituximab is an antibody that attaches to specific cellular components called phospholipids found on the surface of virus particles, including influenza and certain other virus strains, as well as on the outer surface of human host cells only when they are infected with these viruses. Bavituximab helps stimulate the body's natural immune defenses to destroy both the virus particles and the infected cells, without affecting healthy cells. Bavituximab is in Phase 1 clinical trials for hepatitis C virus infections and for solid tumor cancers. A Phase 1b repeat dose study in HCV patients is expected to start in June.

Dr. Thorpe's ASM presentation, Broad-Spectrum Anti-Virals, is scheduled for May 24th at 10:00am in Room 208A as part of a symposium on Bioterrorism: Challenges and Opportunities.

PPHM is breaking out.....

Should close at the HOD...gapper tomorrow.

PPHM IS SETTING ITSELF FOR A LATE-DAY RALLY...

HUGE BIDS POPPING UP.....

BIRD FLU NEWS WILL BE ALL OVER THIS EVENING...SHOULD BE A GAPPER/RUNNER TOMORROW

Terabemo - do you just make stuff up? "Huge bids popping up"? The is no evidence of that. "Gapper/Runner tomorrow"? It was a gapper today and it ran the wrong way. A gap up tomorrow is not likely.

BIRD FLU NEWS WILL BE ALL OVER THIS EVENING...SHOULD BE A GAPPER/RUNNER TOMORROW

Quote

Here is why the bird flu stocks dropped off there morning highs.

WHO finds "no evidence" bird flu more contagious in humans, countering early concerns of potential outbreak